NCT07711002
- Conditions
- Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +8 more
- Locations
-
- Research Site Ottawa, Ontario, Canada
- Research Site Montreal, Quebec, Canada
Clinical trial condition
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Explore clinical trials studying Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). Study availability and eligibility vary by location and protocol.
22 public trials
10 recruiting studies
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) trial results
Not Yet Recruiting
RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
NCT07645326
- Conditions
- Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Locations
-
- Georgetown University Medical Center- Lombardi Comprehensive Cancer Center Washington D.C., District of Columbia, United States
Not Yet Recruiting
Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial
NCT07650240
- Conditions
- Adenocarcinoma of the Prostate, Advanced Prostate Adenocarcinoma, Advanced Prostate Cancer, +19 more
- Locations
-
- Mayo Clinic in Rochester Rochester, Minnesota, United States
Not Yet Recruiting
PSMA PET/CT-Guided SBRT Plus Darolutamide in mHSPC
NCT07649421
- Conditions
- Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Locations
-
- West China Hospital, Sichuan University Chengdu, Sichuan, China
Not Yet Recruiting
CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer
NCT07268794
- Conditions
- Adenocarcinoma, Carcinoma, Genital Diseases, +14 more
- Locations
-
- Fudan University Shanghai Cancer Center Shanghai, China
NCT06312670
- Conditions
- Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +14 more
- Locations
-
- University Hospitals Cleveland Medical Center Seidman Cancer Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States
- Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States
NCT03899467
- Conditions
- Metastatic Castrate Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Locations
-
- University Cancer & Blood Center Athens, Georgia, United States
- Norton Cancer Institute Louisville, Kentucky, United States
- Chesapeake Urology Research Associates Towson, Maryland, United States
- G U Research Network Omaha, Nebraska, United States
Active, Not Recruiting
A Study to Learn More About How Safe Darolutamide is Under Real-world Conditions in Participants With Metastatic Hormone-Sensitive Prostate Cancer
NCT06010914
- Conditions
- Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Locations
-
- Many Locations Multiple Locations, Japan
Active, Not Recruiting
Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression
NCT05683964
- Conditions
- Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +10 more
- Locations
-
- Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
Active, Not Recruiting
PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer
NCT06479187
- Conditions
- Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +10 more
- Locations
-
- Dana Farber Cancer Institute Boston, Massachusetts, United States
- Dana-Farber Cancer Institute Boston, Massachusetts, United States